source
- Patient advocates and experts raise alarm over safety of Neurocrine Biosciences rare disease drugTwo months after an open letter highlighted possible safety issues, patient advocacy groups and several experts are publicly voicing growing alarm about a rare disease therapy marketed by Neurocrin…
- Syndax halts Niktimvo trial for idiopathic pulmonary fibrosis after mid-stage failureSyndax announced it will stop testing Niktimvo (axatilimab) in idiopathic pulmonary fibrosis after the Phase 2 MAXPIRe trial failed to meet its primary endpoint. The study enrolled 145 patients an…